Immuthera at BIO International Convention 2025

Mariusz Jablonski, Chief Business Officer, and Dan Shelly, Chief Business Development Officer at Immuthera and its parent company PolTREG, held dozens of insightful meetings with representatives from big pharma, investment funds, physicians and leading scientists.

We’re proud of the growing interest in our innovative pipeline, which includes the development of multiple cellular therapies: polyclonal Tregs, CAR-TREGs, multi-edited/allogeneic CAR-Tregs, antigen-specific Tregs, and mRNA immunotherapies – all aimed at transforming the treatment of autoimmune diseases.

Thank you to everyone who met with us in Boston – we’re excited about the opportunities ahead!